AriBio Co., Ltd. to Present Biomarker Data for AR1001 from the Mild to Moderate Alzheimer’s Disease Phase 2 Study at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD™ 2023)
31.3.2023 19:00:00 EEST | Business Wire | Press release
AriBio Co., Ltd. announced that David Greeley MD, Chief Medical Officer at AriBio, will present biomarker data from the completed phase 2 study in patients with mild to moderate Alzheimer’s disease who were treated with 10mg and 30mg of AR1001. AR1001 is a potent PDE5 inhibitor with preliminary efficacy in cognition, and preclinical effects on neuron apoptosis inhibition, promotion of neurogenesis, increase in neuroplasticity, and stimulation of autophagy to remove toxic proteins.
The phase 2 study was a double-blind, randomized, placebo-controlled, multi-center trial to evaluate the safety and preliminary efficacy of AR1001 over 26 and 52 weeks of treatment in patients with mild to moderate Alzheimer’s disease. The trial enrolled 210 patients at 21 research centers in the United States.
Plasma collected from patients at baseline, week 26 and week 52 was analyzed by Quantarix using the Simoa HD-X analyzer. Meaningful, statistically significant changes were found over 52 weeks of treatment in a post-hoc analysis, including a dose dependent decline of pTau181 at 26 weeks, and further declines after 52 weeks of treatment. Patients randomized to 10 and 30 mg AR1001 treatment after 26 weeks of treatment with placebo also demonstrated similar declines in pTau181. Other plasma markers including NfL, GFAP and AB42/40 ratio were also measured but showed minimal change or no statistical differences over baseline levels.
AriBio initiated a phase 3 pivotal trial with 30mg of AR1001 to be administered daily to early and mild Alzheimer’s disease patients in December of 2022. Enrollment is expected to continue through 2024. “This biomarker data helps bolster the positive effects seen in cognition with the high dose of AR1001 in the Phase 2 study in mild AD patients. We will continue to collect both CSF and plasma as part of the phase 3 study to analyze as supportive data,” stated Dr. Greeley.
About AR1001-ADP3-US01
AR1001-ADP3-US01 (NCT05531526) is a Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 over 52 Weeks in Participants with Early Alzheimer’s Disease. The study aims to assess the efficacy and safety of AR1001 in slowing the progression of Alzheimer's disease through various cognitive and functional assessments. The details of the clinical trial are available at ClinicalTrials.gov.
About AriBio
AriBio Co., Ltd. is a biopharmaceutical company based in South Korea with offices in the United States. The company focuses on the development of novel therapies for neurodegenerative diseases including Alzheimer’s disease. The company continues to expand its partnerships to accelerate best-in-class treatment options and further advancements in the field of medicine.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230331005009/en/
Contact information
James Rock jimrock@aribiousa.com
AriBio USA Branch
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cambridge Drives a New Era of Digital Maturity for the Age of AI24.2.2026 09:10:00 EET | Press release
As digital literacy moves to the forefront of education reforms worldwide, the International Education group at Cambridge University Press & Assessment (Cambridge) today announces a major transformation of its Cambridge Primary and Lower Secondary Digital Literacy curricula, redefining what it means for young people to thrive in an AI-powered world. Designed for learners aged 5–14, the updated Cambridge Primary Digital Literacy and Lower Secondary Digital Literacy go beyond teaching children how to use technology. They foster digital maturity, equipping students with the judgement, critical thinking and confidence to decide why, when and how technology should be used. The refreshed curricula provide schools with a clear, future-facing framework that empowers learners to retain agency in a rapidly evolving digital landscape. New content ranges from online wellbeing to prioritising human intelligence in the age of AI while exploring the challenges and the value that AI can bring to their
Cubans Protest EU Financing of Havana Regime Amid Rising Tensions24.2.2026 09:05:00 EET | Press release
Cubans from across the United States gathered today in Washington, D.C., outside the Delegation of the European Union, to denounce the EU’s complicity in financing Cuba’s communist state. Protesters held signs reading, “EU, don’t fund the dictatorship,” “Democracies should not fund dictatorships,” and “This march would get me killed in Cuba.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223106922/en/ Cubans from across the United States gathered yesterday in Washington, D.C., outside the Delegation of the European Union, to denounce the EU’s role in financing Cuba’s communist state. The demonstration featured leading Cuban opposition groups including the Assembly of the Cuban Resistance and Cuban Freedom March along with former Cuban political prisoners, Veterans of the Bay of Pigs, Florida State Senator Alexis Calatayud, Miss Universe Cuba 2025 Lina Luaces, and television personality Lili Estefan. Photo: Assembly of th
Epredia and Mindpeak Announce EU Distribution Agreement for AI-Powered Image Recognition in Cancer Diagnostics24.2.2026 09:00:00 EET | Press release
Epredia, a global leader in precision cancer diagnostics and a subsidiary of PHC Holdings Corporation (TSE: 6523), and Mindpeak, a leading provider of artificial intelligence (AI) solutions for clinical and research pathology, today announced a distribution agreement to bring Mindpeak’s AI-based image recognition software to Epredia’s digital pathology customers in the European Union. As cancer cases increase and diagnostic processes become more complex, pathology laboratories are under pressure to speed up processes and reduce costs. Mindpeak’s AI technology delivers instant, pixel-level analysis of digital images of tissue samples, enabling objective and reproducible assessments in breast cancer, lung cancer, gastrointestinal pathology, biomarker quantification and exploratory research studies. These tools are designed to reduce variability, support decision-making and improve workflow efficiency, all without requiring cloud connectivity, thereby offering data privacy and security fo
The Empire State Building Presents First-Ever Children’s Birthday Party Package for Celebrations at the Iconic Observatory Experience23.2.2026 16:13:00 EET | Press release
Parents who have looked for the best birthday party idea for their children have had their wish fulfilled. Today, the Empire State Building (ESB) announced the debut of its first-ever ESB Birthday Party Package for kids at the international icon’s Observatory as part of year-long 95th anniversary celebrations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223161708/en/ The Empire State Building Presents First-Ever Children’s Birthday Party Package for Celebrations at the Iconic Observatory Experience “From Lego playtime to Percy Jackson readers, children love the Empire State Building and now parents can give an unmatched experience to their children and their friends,” said Anthony E. Malkin, chairman and CEO of Empire State Realty Trust. “This birthday party package tops them all with an escorted visit through our world-famous Observatory, a private party room with a Ghirardelli sundae chef, Empire State Building party
CoolMPS™ 600: Accurate and Affordable Long MPS/NGS Reads on a Mid-Throughput Platform23.2.2026 16:00:00 EET | Press release
Swiss Rockets AG announces that its CoolMPS 600 mid-throughput sequencer with advanced chemistry and novel MPS/NGS read length will become available in Q2 2026. Enabled by its exclusive license of CoolMPS technology, Swiss Rockets AG is developing its first sequencer, CoolMPS 600, through contract R&D with Complete Genomics since August 2025. The platform is utilizing the company’s proprietary antibody-based CoolMPS™ chemistry combined with DNBSEQ™, a real PCR-free DNA nanoarray technology. Separately, Swiss Rockets AG announced that it has entered into a definitive agreement to acquire 100% ownership of Complete Genomics. CoolMPS 600 enables cost-effective extended single-end sequencing to 600 bases (SE600) while maintaining high base accuracy. The system is designed to support advanced whole-genome sequencing (WGS) with improved mapping accuracy across complex genomic regions, including better detection of structural variants. It also enables full length transcriptomes and more infor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom